clinical trial · NCT05725070
Phase 0/1 Study of 212Pb-NG001 in mCRPC
Metastatic Castration-resistant Prostate Cancer212Pb-NG001
brief summary
The purpose of this study is to evaluate the imaging feasibility and safety of 212Pb-NG001.
started
Mar 6, 2023
primary completion
Jul 6, 2023
completion
Jul 6, 2023
last updated
Oct 6, 2023
detailed description
This is a single site, open label, non-randomized, non-controlled intervention study with an initial microdosing run-in part (phase 0), followed by a conventional dose-escalation phase 1 part.
official title
Phase 0/1 Theragnostic Study in Patients With Metastatic Castration Resistant Prostate Cancer in Need of Salvage Therapy, Selected by 18F-PSMA-PET Imaging and Treated by Alpha-therapeutic Radioligand 212Pb-NG001
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol